Exploration of pharmacological interventions to prevent isoproterenol-induced myocardial infarction in experimental models

Ther Adv Cardiovasc Dis. 2014 Aug;8(4):155-169. doi: 10.1177/1753944714531638. Epub 2014 May 9.

Abstract

High incidences of myocardial infarction associated with high morbidity and mortality, are a major concern and economic burden on industrialized nations. Persistent β-adrenergic receptor stimulation with isoproterenol leads to the development of oxidative stress, myocardial inflammation, thrombosis, platelet aggregation and calcium overload, which ultimately cause myocardial infarction. Therapeutic agents that are presently employed for the prevention and management of myocardial infarction are beta-blockers, antithrombotics, thrombolytics, statins, angiotensin converting enzyme inhibitors, angiotensin II type 1 receptor blockers, calcium channel blockers and nitrovasodilators. In spite of effective available interventions, the mortality rate of myocardial infarction is progressively increasing. Thus, there has been a regular need to develop effective therapies for the prevention and management of this insidious disease. In this review, the authors give an overview of the consequences of isoproterenol in the pathogenesis of cardiac disorders and various therapeutic possibilities to prevent these disorders.

Keywords: atherosclerosis; calcium overload; inflammation; isoproterenol; oxidative stress; reactive oxygen species.

Publication types

  • Review